Assembly Biosciences Plans $250 Million Offering Assembly Biosciences has filed for a mixed shelf offering of up to $250 million, aiming to bolster its financial position. The company continues to focus on its innovative antiviral pipeline, with significant progress in treatments for herpes, hepatitis B, and hepatitis delta virus, as highlighted in recent updates.156